PYC THERAPEUTICS LIMITED — Capital/Financing Update 2019

Oct 30, 2019

Market Announcement

==> picture [33 x 50] intentionally omitted <==

31 October 2019

==> picture [451 x 5] intentionally omitted <==

Phylogica Limited (ASX: PYC) – Trading Halt

Description

The securities of Phylogica Limited (‘PYC’) will be placed in trading halt at PYC’s request, pending it releasing an announcement about the outcome of the institutional component of the accelerated entitlement offer. Unless ASX decides otherwise, the securities will remain in trading halt until the commencement of normal trading on Monday, 4 November 2019.

Issued by

Daniel Nicholson

Adviser, Listings Compliance (Perth)

Market Announcement 1/1 ASX Customer Service Centre 131 279 | asx.com.au

31 October 2019 ASX Limited

==> picture [86 x 48] intentionally omitted <==

31 October 2019

Listings Compliance (Perth) ASX Compliance Pty Ltd Level 40, Central Park 152 - 158 St George's Terrace Perth WA 6000

By email: tradinghaltsperth@asx.com.au

Phylogica Limited (ASX:PYC) - Request for Trading Halt

Pursuant to ASX Listing Rule 17.1, Phylogica Limited ACN 098 391 961 ( Company ) requests that the ASX grants a trading halt with respect to the Company's shares.

The Company provides the following information regarding this request:

1. the reason for the trading halt is that the Company intends to make an announcement regarding an accelerated non-renounceable entitlement offer;

2. the Company requests that the trading halt continues until the earliest of:

   • (a) the Company making an ASX announcement regarding the outcome of the proposed capital raising;

   • (b) the open of trading on 4 November 2019; and

   • (c) the Company separately requesting that the trading halt be lifted.

3. the Company expects that the ASX announcement will be made as soon as possible, and in any event, prior to the open of trading on 4 November 2019;

4. the Company considers that the trading halt is necessary as otherwise trading in the Company's shares would continue on an uninformed basis; and

5. the Company is not aware of any reason why a trading halt should not be granted or any other information necessary to inform the market about the requested trading halt.

Yours faithfully

==> picture [123 x 39] intentionally omitted <==

Kevin Hart Company Secretary Phylogica Limited

Tel: +61 8 6151 0992| pyctx.com

Phylogica Limited trading as PYC Therapeutics ACN 098 391 961

==> picture [426 x 38] intentionally omitted <==